百力司康港股IPO招股书失效

Group 1 - BlissBio Inc. submitted its Hong Kong IPO prospectus on June 29, which became invalid after six months on December 29, with Goldman Sachs, Huatai International, and Jianyin International as joint sponsors [1] - BlissBio Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation antibody-drug conjugates (ADCs) to address significant unmet needs in cancer treatment [2] - The company's core product, BB-1701, is a human epidermal growth factor receptor 2 (HER2) targeted ADC candidate primarily aimed at treating breast cancer (BC), non-small cell lung cancer (NSCLC), and potentially other HER2-expressing cancers [2]